Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
0(0%)
Results Posted
125%(5 trials)
Terminated
2(22%)

Phase Distribution

Ph phase_2
1
11%
Ph phase_4
5
56%
Ph not_applicable
1
11%
Ph phase_1
1
11%

Phase Distribution

1

Early Stage

1

Mid Stage

5

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
1(12.5%)
Phase 4Post-market surveillance
5(62.5%)
N/ANon-phased studies
1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

44.4%

4 of 9 finished

Non-Completion Rate

55.6%

5 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(4)
Terminated(5)

Detailed Status

Completed4
Withdrawn3
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (12.5%)
Phase 21 (12.5%)
Phase 45 (62.5%)
N/A1 (12.5%)

Trials by Status

withdrawn333%
completed444%
terminated222%

Recent Activity

Clinical Trials (9)

Drug Details

Intervention Type
DRUG
Total Trials
9